1. Polyvinylpyrrolidone-curcumin nanoparticles with immune regulatory and metabolism regulatory effects for the treatment of experimental autoimmune uveitis.
- Author
-
Cao F, Liang K, Tang WW, Ni QY, Ji ZY, Zha CK, Wang YK, Jiang ZX, Hou S, Tao LM, and Wang X
- Subjects
- Animals, Humans, Cell Line, Retinal Pigment Epithelium drug effects, Retinal Pigment Epithelium metabolism, Rats, Female, Rats, Inbred Lew, Blood-Retinal Barrier drug effects, Blood-Retinal Barrier metabolism, Male, Curcumin administration & dosage, Curcumin pharmacology, Curcumin chemistry, Curcumin therapeutic use, Uveitis drug therapy, Uveitis immunology, Uveitis metabolism, Povidone chemistry, Povidone administration & dosage, Nanoparticles administration & dosage, Nanoparticles chemistry, Autoimmune Diseases drug therapy, Oxidative Stress drug effects
- Abstract
Uveitis comprises a cluster of intraocular inflammatory disorders characterized by uncontrolled autoimmune responses and excessive oxidative stress leading to vision loss worldwide. In the present study, curcumin (CUR) was conjugated with polyvinylpyrrolidone (PVP) to form PVP-CUR nanoparticles with significantly elevated solubility and outstanding multiple radical scavenging abilities. In vitro studies revealed that PVP-CUR nanoparticles markedly mitigated oxidative stress and reduced apoptosis in a H
2 O2 -induced human retinal pigment epithelial cell line (ARPE-19) and promoted phenotypic polarization from M1 to M2 in an LPS-induced human microglial cell line (HMC3). Further in vivo studies demonstrated the prominent therapeutic effects of PVP-CUR nanoparticles on experimental autoimmune uveitis (EAU), which relieved clinical and pathological progression, improved perfusion and tomographic manifestations of retinal vessels, and reduced blood-retinal barrier (BRB) leakage; these effects may be mediated by mitigating oxidative stress and attenuating macrophage/microglia-elicited inflammation. Notably, treatment with PVP-CUR nanoparticles was shown to regulate metabolite alterations in EAU rats, providing novel insights into the underlying mechanisms involved. Additionally, the PVP-CUR nanoparticles showed great biocompatibility in vivo. In summary, our study revealed that PVP-CUR nanoparticles may serve as effective and safe nanodrugs for treating uveitis and other oxidative stress- and inflammation-related diseases., Competing Interests: Declaration of competing interest The authors declare no competing financial interest., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF